Abstract: Methods of modulating the properties of a cell culture expressing a protein of interest are provided. In various embodiments the methods relate to the addition of cell cycle inhibitors to growing cell cultures.

Abstract: Included are embodiments of a system for monitoring device usage. The system may include a handheld device for performing an action, where the handheld device includes an engagement sensor and a computer that includes a processor and a memory component. The memory component stores logic that causes the computer to determine a minimum device engagement time of the handheld device. In some embodiments, the logic causes the computer to receive output data from the engagement sensor, where the output data includes an actual device engagement time, determine if the actual device engagement time is at least as long as the minimum device engagement time, and in response to determining that the actual device engagement time is at least as long as the minimum device engagement time, determine the action taken by the handheld device.

Abstract: Compounds of Formula (I) are useful as modulators of glycosylation. Compounds of Formula (I) have the following structure: (I) and the definitions of the other variables are provided herein.

Abstract: Compounds of Formula (I) are useful as modulators of glycosylation. Compounds of Formula (I) have the following structure: (I) and the definitions of the other variables are provided herein.

Abstract: Methods of modulating the properties of a cell culture expressing a protein of interest are provided. In various embodiments the methods relate to the addition of cell cycle inhibitors to growing cell cultures.

Abstract: A ring laser gyroscope configured to reduce alignment shifts in at least one critical alignment of the ring laser gyroscope is provided. The ring laser gyroscope includes reflective components configured to direct clockwise optical beams and counter-clockwise optical beams in at least one lasing plane; at least one ring-laser-gyro mounting feature having at least one respective through hole; and at least one minimally-threaded screw positioned in the at least one respective through hole. An unthreaded section of the minimally-threaded screw is contactlessly encased in the at least one respective through hole. A threaded-end of the at least one minimally-threaded screw is threaded in a respective at least one threaded hole in a gyro frame, the gyro frame spanning a reference mounting plane.

Abstract: Methods of modulating the properties of a cell culture expressing a protein of interest are provided. In various embodiments the methods relate to the addition of cell cycle inhibitors to growing cell cultures.

Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where: R6 is —S—R14; and other substituents are as defined in the specification.

Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where R6 is —C?C—R10, —CH?CR11R11?, or —(C0-C8)alkyl-Ar2 optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents and other substituents are as defined in the specification.

Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where: R6 is —S—R14; and other substituents are as defined in the specification.

Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where: R6 is —C?C—R10, —O—R12, —S—R14, or —NR24R25; and other substituents are as defined in the specification.

Abstract: An injection system and method is described. In several exemplary embodiments, the injection system and method may be a part of, and/or used with, a system and method for excavating a subterranean formation. In at least one example, an apparatus is provided that includes a source of impactors comprising at least some ferritic material capable of influence by magnetic fields. An injector is coupled to the source and includes a screw extruder, a screw positioned within a barrel, and at least one magnetic circuit is positioned outside of the barrel.

Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2C receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: R6 D R?N—R?R* where R6 is —(CrC3)alkyl-S—(C0-C3)alkyl-R10, —(C1-C3)alkyl-NR11R12, —(CrC3)alkyl-O—R13. and other substituents are as defined in the specification.

Abstract: A system and method for excavating a subterranean formation, according to which a suspension of liquid and a plurality of impactors is introduced into at least one cavity formed in the body member. The suspension is discharged from a nozzle disposed in the cavity towards the formation so that the impactors remove at least a portion of the formation.

Abstract: The present invention discloses novel compounds of Formula I: (I) possessing 11?-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11?-HSD type 1 activity.

Abstract: A system and method for excavating a wellbore through a subterranean formation that includes a drill string having an inner passage for flowing a suspension of fluid and impactors. The drill string includes a flow control device to block flow in the drill string passage or in the annulus formed between the drill string and the wellbore inner wall from lowing into the bit when flow is reduced or stopped. The flow can take place due to fluid density differences resulting from impactors being in suspension in the fluid. The flow control device includes a selectively openable and closable valve. Valve embodiments include valves having flapper elements, a plurality of cables suspended in an annular configuration, and whisker elements.

Abstract: The present invention discloses compounds of Formula I: (I) having 11beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as the use of the Formula I and compositions as medicaments to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, Syndrome X, and other conditions associated with hyperglycemia.

Abstract: The present invention discloses compounds of Formula I: (I) having 11beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as the use of the Formula I and compositions as medicaments to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, Syndrome X, and other conditions associated with hyperglycemia.

Abstract: An injection system and method is described. In several exemplary embodiments, the injection system and method may be a part of, and/or used with, a system and method for excavating a subterranean formation.

Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzoazepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where: R6 is -C?C-R10, -O-R12, -S-R14, or -NR24R25; and other substituents are as defined in the specification.